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Background:  Kyphoscoliosis  is  a  skeletal  condition  involving  the  hyperﬂexion  of  the  thoracic
spine. It  is  characterized  by  reduced  chest  wall  compliance  and  impaired  respiratory  mecha-
nisms leading  to  progressive  hypo-ventilation.  We  evaluated  the  effectiveness  and  the  safety
of non-invasive  ventilation  (NIV)  in  patients  after  an  episode  of  acute  respiratory  failure  (ARF).
Methods: Eighteen  patients  with  severe  kyphoscoliosis  who  had  been  hospitalized  for  an  episode
of ARF  were  followed  for  4  years.  NIV  was  applied  via  mouthpiece  (MPV)  during  the  daytime  and
via mask  during  the  night.  The  primary  outcomes  were  changes  in  physiological  and  functional
parameters  as  well  as  quality  of  life.  Secondary  outcomes  were  considered  re-hospitalization
and mortality  rate  after  discharge.  A  set  of  control  subjects  was  used  for  comparison.
Results:  All  patients  showed  a  signiﬁcant  improvement  in  several  clinical,  physiological,  func-
tional and  quality  of  life  parameters.  Four  of  them  (22.2%)  died  during  the  four  year  follow-up
period.  In  the  uni-variate  analysis  patients  who  died  had  higher  cardiac  co-morbidity,  lower  MIP
and SNIP,  higher  paCO2,  and  oxygen  desaturation  index  at  initial  admission.
Conclusions:  Diurnal  MPV  associated  with  nocturnal  NIV  had  signiﬁcantly  improved  lung  func-
tion, clinical  outcomes  and  quality  of  life.  It  should  be  considered  as  a  safe  alternative  to
traditional  administering  of  NIV.
© 2015  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.U.  This  is
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yphoscoliosis  is  a  condition  characterized  by  reduced
hest  wall  compliance  and  impaired  respiratory  mecha-
isms  leading  to  progressive  respiratory  muscle  weakness
ypoventilation,  hypercapnia,  and  chronic  respiratory
ailure.1,2 Acute  exacerbations  are  most  often  due  to
espiratory  tract  infections  which  worsen  the  respiratory
ondition.  This  decline  leads  to  acute  respiratory  fail-
re  (ARF),  which  may  require  admission  to  intensive  care
ICU)  with  either  non  invasive  or  invasive  mechanical
entilation.1,3 Non-invasive  ventilation  (NIV)  is  the  standard
ong-term  treatment  because  it  improves  hypoventilation
ymptoms  and  reduces  sleep  fragmentation  as  well  as
ecreasing  hospital,  and  ICU  admissions.1,3--6 Home  NIV  origi-
ally  started  during  the  poliomyelitis  epidemic  over  50  years
go.7,8 It  continues  to  be  useful  because  of  the  increased
umber  of  patients  who  would  otherwise  remain  in  the
CU  simply  because  of  their  ventilator  dependence,4 in  this
ay  exposing  the  patients  to  iatrogenic  complications  and
ecreasing  their  quality  of  life,  and  also  increasing  costs
nd  it  is  well-known  that  the  ﬁnancial  burden  is  an  impor-
ant  factor  in  every  health-care  system.  To  avoid  these
roblems,  extubation  with  a  safe  mode  of  mechanical  ven-
ilation  is  needed.1 Pneumonia,  respiratory  infections  and
ardiac  co-morbidities  are  the  most  common  reasons  for
ospitalization.1,3,9,10 In  kyphoscoliotic  patients  affected  by
RF,  NIV  has  a  high  rate  of  success  (about  75%).1 It  tends
o  fail  in  patients  with  more  severe  illnesses  (patients  with
epsis  and  higher  APACHE  II  scores,  and  lower  Glasgow  Coma
core  (GCS)  and  pH  values).1,7,10 Patients  may  be  started
n  NIV  in  the  ICU  or  in  the  High  Dependency  Unit  during
RF  where  there  is  minimal  independent  respiratory  func-
ion  or  it  may  be  introduced  electively  in  patients  with
rogressive  ventilator  insufﬁciency.8 Patients  with  chronic
entilatory  insufﬁciency  associated  with  thoracic  restrictive
isease  derive  beneﬁt  from  long-term  ventilation  in  numer-
us  ways,  from  improvement  in  arterial  blood  gases  (ABG)  to
ncreased  survival  rates.7,8,11 Mouthpiece  ventilation  (MPV)
s  a  technique  that  is  useful  in  the  treatment  of  chronic
entilatory  failure,  particularly  in  neuro-muscular  patients
here  it  has  been  used  for  more  than  half  a  century.4,6 MPVs  particularly  useful  when  there  are  problems  with  con-
entional  masks.  The  aim  of  this  study  is  to  present  the
utcomes  of  kyphoscoliosis  patients  admitted  to  a  dedicated
nit  for  pulmonary  rehabilitation  after  an  episode  of  ARF,  to
Table  1  The  demographic  and  anthropometrics  character-
istics  of  the  MPV  patients.
Parameter  Mean  ±  SD  Range
Age  (years)  71  ±  11  44--82
Weight (kg)  74  ±  7  52--81
Height (cm) 169  ±  8  149--175
BMI 26  ±  6 23--33
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valuate  the  effectiveness  and  safety  of  adding  MPV  to  noc-
urnal  NIV  in  patients  with  severe  ventilatory  failure  and
ong  term  NIV  (>12  h  ventilation  per  day),12 and  identify  risk
actors,  readmission  and  death.  NIV  failure,  number  of  hos-
ital  re-admissions,  and  mortality  at  180-day,  1-year,  2  years
nd  4-years  mortality  are  examined.  Changes  in  clinical  and
unctional  respiratory  and  quality  of  life  parameters  after
aytime  treatment  with  MPV  plus  nasal  mask  ventilation  dur-
ng  the  night  are  presented.  Finally,  we  have  compared  the
utcomes  of  our  cohort  with  a  population  of  an  eighteen
ontrol  patients  treated  only  with  nocturnal  NIV.
aterials and methods
ighteen  patients  were  admitted  to  our  institution  after  an
pisode  of  ARF.  After  discharge  each  was  followed  for  four
ears.  All  had  severe  kyphoscoliosis  with  a  Cobb  angle  >80◦.
welve  patients  had  idiopathic  kyphoscoliosis,  three  post-
oliomyelitis  spinal  defects,  and  three  post-tuberculosis
omplications  (Pott’  s  disease).  Their  demographic  and
nthropometric  data  are  shown  in  Table  1. All  patients  were
ew  to  our  center.  Each  had  been  admitted  to  ICU  or  Emer-
ency  Department  and  treated  with  invasive  or  non-invasive
entilation.  None  had  used  long-term  oxygen  therapy  or
IV  before  this  study.  Inclusion  criteria  were  based  on
linical  symptoms  including  morning  headache,  fatigue,  dys-
nea,  ability  to  collaborate,  and  consciousness  (GCS  ranging
etween  13  and  15.).  Respiratory  insufﬁciency  associated
ith  mild/moderate  acidosis  (pH  ranging  between  7.35  and
.30)  with  persistent  hypercapnia  (paCO2 >  50  mmHg)  was
ocumented  in  each  subject.  Absence  of  systemic  inﬂam-
ation  (leukocytes  <  10,000/L),  pulmonary  parenchymal
isease,  and  absence  of  recent  antibiotic  treatment  were
lso  necessary  for  inclusion.  Exclusion  criteria  included
mpaired  consciousness  (GSC  <  13),  initial  pH  <  7.30,  history
f  bronchial  asthma,  symptomatic  cardiovascular  disease,
urrent  history  of  smoking,  inability  to  use  MPV  and/or
efusal  to  use  NIV.
tudy  design
he  study  was  conducted  in  a  four-bed  Respiratory
ehabilitation  Unit  dedicated  to  the  care  of  patients  requir-
ng  non-invasive  mechanical  ventilation.  The  study  was
esigned  as  prospective  observational  study  between  May
010  and  September  2014.  The  study  was  carried  out
ccordance  with  the  Helsinki  Declaration  and  approved  by
he  local  Ethics  Committee.  All  patients  provided  written
nformed  consent  before  beginning  the  study.  The  study
as  registered  with  Chinese  Clinical  Trials  as  Chi  CTR-OPC
5006661.
easurements
efore  explaining  the  NIV  protocol  to  each  patient,  we  eval-
ated  dyspnea  (Modiﬁed  Medical  Research  Council  (MMRC)
yspnea  scale),  Epworth  scale  (ESS),  and  SAT-P.13,14 The
atient  was  asked  to  assess  on  a  Visual  Analog  Scale  (VAS)
is/her  satisfaction  on  32  life  aspects  of  his/her  health
tatus.  It  provides  32  individual  scores  and  ﬁve  factors
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100  (highest  level  of  satisfaction).13,14 Static  and  dynamic
lung  volumes15 and  respiratory  muscle  strength  (maximal
inspiratory  pressure-MIP,  maximal  expiratory  pressure-MEP,
sniff  nasal  inspiratory  pressure-SNIP)  were  measured  (Sen-
sormedics  VMax  62J  Body  Plethysmography,  CareFusion  San
Diego,  USA).16 Values  of  MIP  and  MEP  were  obtained  at  close
to  residual  volume;  total  lung  capacity  levels  and  SNIP  val-
ues  were  determined.14 Ventilatory  drive  was  evaluated  by
measuring  the  inspiratory  occlusion  pressure  for  the  ﬁrst
100  ms  of  inspiration  (P01)  with  the  patient  sitting  at  rest  and
breathing  room  air17 (Jaeger  Masterscreen  Pneumo  Spirom-
eter).  Arterial  blood  gases  were  measured  when  patient
awoke  (Siemens  Rapid  Point  405).  Blood  samples  were  ana-
lyzed  for  pH,  PaCO2,  PaO2,  and  HCO3−.  The  CRM  of  nocturnal
events  was  performed  with  a  portable  device  6-channel
polygraphy  (SOMNO  Check  Effort,  Weinmann  V2.05).18 Respi-
ratory  nocturnal  episodes  (apnea,  hypopnea,  desaturation)
were  deﬁned  according  to  the  Canadian  Thoracic  Society
guidelines.19 Trans-cutaneous  CO2 pressure  (tcPCO2)  was
performed  using  Sen-Tec  digital  monitor.20 Finally  functional
exercise  capacity  was  determined  using  the  six  minute  walk
test  (6  MWT).21
Non  invasive  ventilation  protocol
NIV  was  applied  via  an  angled  mouthpiece  (15  or  22  mm  as
preferred  by  the  patient)  during  the  daytime  and  via  nasal  or
oro-nasal  mask  during  the  night.  The  mask  that  was  the  best
suited  to  the  patient’s  anatomic  characteristics  and  the  ven-
tilator  which  provided  the  greatest  comfort  were  selected.
All  the  patients  started  using  assisted  controlled  ventilation
in  volume  (ACV)  during  the  daytime.  The  ventilator  setting
was  tidal  volume  800--1400  ml  respiratory  rate  2  rates/min
as  previously  described.22 The  patients  gradually  became
accustomed  to  the  mouthpiece  after  two  to  four  supervised
morning  and  afternoon  training  sessions.  During  the  night,
patients  were  treated  using  assisted  controlled  ventilation
mode  in  volume  (ACV)  or  if  they  preferred  assisted  pressure
controlled  mode  (APCV).  The  nocturnal  ventilatory  setting
was  volume  cycled:  tidal  volume  10--12  ml/kg  respiratory
rate  16  rates/m′ and  pressure-cycled  inspiratory  pressure
15--20  cmH2O  expiratory  pressure  2--3  cmH2O  or  lower,  as
previously  described.5,8 NIV  (both  nocturnal  and  diurnal)  was
implemented  using  the  following  ventilators:  Breas  VIVO  50
or  Resmed  Elisee  150.  Six  patients  used  double  limb  venti-
lator  circuit;  12  patients  used  single  limb  ventilator  circuit
with  expiratory  valve.  The  effectiveness  of  NIV  treatment
was  evaluated  by  ABG  analysis  with  the  aim  of  achieving
a  pH  above  7.35,  paCO2 <  45  mmHg  and  paO2 >  60  mmHg.
If  SatO2 >  90%  was  not  achieved,  supplemental  oxygen  was
added.
Follow-up
After  discharge,  the  patients  had  access  to  the  medical
staff  by  telephone  and  were  followed  for  four  years.  In  the
3rd,  6th,  12th,  24th,  36th,  48th  month  the  patients  were
evaluated.  We  examined  symptoms,  re-admissions,  and  NIV
compliance.  Six  months  after  discharge  we  did  complete
pulmonary  function  tests  with  respiratory  functional  param-
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utcomes
he  primary  outcome  was  the  impact  of  MPV  on  short
linical,  physiological  functional  parameters  and  HRQL.  Sec-
ndary  outcomes  were  considered  short-term  and  long-term
ospitalization  and  mortality  after  starting  of  MPV  (180--360
ays,  two  years,  and  four  years).  Risk  factors  for  mortality
ere  evaluated  as  well.
tatistical  analysis
ll  data  were  collected  in  a  databank  (Microsoft  Access)  and
nalyzed  with  R-Project  software  Version  2.13.2.  Analysis  of
ovariance  was  used  to  test  for  changes  in  both  paramet-
ic  and  non  parametric  data  at  two  different  time  points.
ssessment  of  baseline  data  between  survivors  and  deceased
atients  were  performed  with  uni-variate  regression  analy-
is.  Results  are  presented  as  mean  values  ±  SD  for  qualitative
ariables  and  as  frequencies  and  percentages  for  qualita-
ive  and  ordinal  variables.  p  values  <0.05  were  considered
igniﬁcant.
esults
entilation  parameters  and  duration  of NIV
ll  patients  were  ventilated  in  ACV  mode  during  the  day
tidal  volume  (VT)  1100  ±  400  ml)  and  ACV  or  APCV  mode
uring  the  night.  Initially  nocturnal  ventilation  was  ACV
ode  in  six  patients;  twelve  chose  APCV  mode.  During  the
reatment  two  patients  switched  from  ACV  to  APCV  mode
ecause  of  side  effects  (aerophagia).  The  settings  for  ACV
ode  were  a  respiratory  frequency  16  ±  2  cycles  with  VT
000  ±  300  ml.  The  settings  for  APCV  were:  inspiratory  pres-
ure  (IPAP)  22  ±  4  cmH2O  and  expiratory  pressure  (EPAP)
 ±  1  cmH2O.  NIV  (diurnal  plus  nocturnal)  was  used  on  aver-
ge  16  ±  3  h  daily  from  discharge  to  six  months.  None  of  the
tudy  patients  used  the  ventilator  for  less  than  12  h  per  day
uring  the  follow-up  period.  NIV  usage  was  determined  by  a
pecialist  nurse  at  every  outpatient  clinic  visit.  She  checked
he  built-in  time  counter  of  the  ventilator.  Four  patients
22.2%)  used  it  less  than  14  h;  ﬁve  patients  (27.8%)  14--16  h
nd  nine  (50%)  patients  more  than  16  h  per  day.
ffects  of  NIV
ll  patients  who  received  MPV  and  nocturnal  NIV  showed
 signiﬁcant  improvement  in  several  clinical  parameters
s  well  in  ABG  parameters  (PaO2/FiO2, PaCO2 and  pH)
nd  improvements  were  observed  in  FVC,  FEV1,  MIP,  MEP
nd  SNIP,  VT,  and  breathing  frequency,  P01.  6MWT  distance
mproved,  but  it  did  not  achieve  statistical  signiﬁcance.
olygraphic  data  also  improved  signiﬁcantly  as  did  tcPCO2.
e  found  a  discrepancy  between  apnea-hypopnea  index
AHI)  and  oxygen  desaturation  index  (ODI)  because  in
ome  patients  we  observed  episodes  of  apnea  in  order  to
o  diaphragmatic  activity  >  10  s  without  signiﬁcant  desat-
ration  >4%.  HRQL  and  SAT-P  scores  related  quality  of
leep  (p  <  0.01);  physical  well-being  (p  <  0.003);  sleep,  eat-
ng,  and  leisure  (p  <  0.02);  self-conﬁdence  (p  <  0.01);  and
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Table  2  Lung  function,  breathing  pattern  and  health-related  quality  of  life  measurement  in  the  MPV  group  at  admission  and
after 6  months  treatment.
Variable  Pre-treatment  (admission)  Post-treatment(after  6  months)  p-value
FVC  1698  ±  493  2216  ±  367  0.02
FVC% 35  ±  6  51  ±  5  0.02
FEV1 1342  ±  388  1647  ±  391  0.04
FEV1%  36  ±  3  52  ±  9  0.03
FEV1/FVC%  80  ±  7  87  ±  3  0.01
TLC 4.390  ±  1045  4600  ±  10.57  0.08
TLC% 68  ±  7  82  ±  8  0.07
VT ml 370  ±  88 428  ±  65 0.03
Breathing  frequency 21  ±  2 16  ±  2 0.004
TI/T TOT 0.44  ±  0.03 0.38  ±  0.02 0.05
VT/TI (ml/sec)  377  ±  121  411  ±  89  0.09
P01 0.24  ±  0.11  0.16  ±  0.05  0.03
P01 max  3.95  ±  1.93  4.96  ±  1.70  0.06
P01/Pmax  0.08  ±  0.02  0.05  ±  0.02  0.83
P01/MV  0.06  ±  0.03  0.05  ±  0.01  0.78
MIP (cmH2O)  38  ±  13  46  ±  9  0.04
MEP (cmH2O)  40  ±  12  45  ±  7  0.08
SNIP 46  ±  8  55  ±  9  0.005
6 MWD  (mt.)  272  ±  57  311  ±  68  0.06
paO2 59  ±  6  66  ±  4  0.06
paCO2 56  ±  6  44  ±  3  0.03
pH 7.35  ±  0.07  7.37  ±  0.01  0.03
HCO3− 32  ±  4  27  ±  4  0.009
PaO2/FiO2 265  ±  28  314  ±  18  0.04
Dyspnea (MMRC  scale)  3  ±  1  2  ±  1  0.06
EPSS (Epworth  Scale)  16  ±  2  8  ±  2  0.004
Apnea-hypopnea  index  (AHI)  26  ±  18  10  ±  4  0.002
Oxygen desaturation  index  (ODI)  20  ±  6  13  ±  3  0.001
Mean oxygen  saturation 86  ±  2  93  ±  1  0.005
Nadir SatO2% 70  ±  8 88  ±  4  0.002
Average drop 8  ±  2  5  ±  1  0.003
Time desat 47  ±  6 11  ±  4  0.002
T 90% 18  ±  4 1  ±  1 0.002
Tc PCO2 mean 56  ±  6 46  ±  4  0.003
SAT-P Amount  and  quality  of  sleep 39.20  ±  21.11 56.66  ±  20.44 0.01
SAT-P Physical  well-  being 40.56  ±  27.88 62.68  ±  19.88 0.003
SAT-P Sleep,  eating,  leisure  45.34  ±  19.57  55.47  ±  16.56  0.02
SAT-P Self-conﬁdence  51.32  ±  26.27  67.21  ±  19.40  0.01
SAT-P Mood  42.16  ±  28.55  61.05  ±  19.88  0.02
paO2, arterial oxygen pressure; paCO2, carbon dioxide arterial pressure; MIP, maximal inspiratory pressure; MEP, maximal expiratory
pressure; SNIP, sniff nasal inspiratory pressure; P01, inspiratory occlusion pressure for the ﬁrst 100 ms of inspiration; VT, tidal volume;
TI, inspiratory time; AHI, apnea hypopnea index; ODI, oxygen desaturation index; tcPCO2, transcutaneous CO2 pressure; FVC, forced


















Council dyspnea scale; PaO2/FiO2, arterial oxygen pressure/fract
ood  (p  <  0.02)  showed  statistically  signiﬁcant  improvement
Table  2).
ospital  re-admissions  and  factors  related  to
ortality
ll  the  patients  were  alive  at  six  months  post  discharge.
ne  patient  with  severe  pulmonary  hypertension  was  admit-
ed  to  ICU  because  of  an  episode  of  severe  ARF  and  died
ine  months  after  initial  discharge.  Another  patient  died





inspired oxygen ratio; SAT-P, Satisfaction Proﬁle.
ied  during  follow-up:  both  were  older  than  75  years  of
ge  and  had  severe  cardiac  or  cardio-pulmonary  (e.g.,  pul-
onary  hypertension)  pathologies.  Both  were  re-admitted
o  ICU  with  severe  ARF.  Clinical  outcomes  are  presented
n  Table  3.  Eight  patients  (44.4%)  were  readmitted  during
ollow-up  to  hospital.  Four  of  the  18  patients  followed  died
22.2%).  Causes  of  readmission  were  mainly  due  to  respira-
ory  infections  (42.9%)  and  severe  ARF.  Uni-variate  analysis
f  mortality  demonstrated  positive  correlations  with  cardiac
o-morbidity,  lower  MIP,  lower  SNIP,  higher  paCO2,  and  oxy-
en  desaturation  index  (ODI)  at  baseline  admission  (Table  4).
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Table  3  Clinical  outcomes  of  patients  treated  with  MPV.
Patients  readmitted  to  hospital  8  (44.4%)
Number  of  readmissions  14  (100%)
ICU readmission  4  (28.5%)
Causes of  hospital  readmission  14
Respiratory  infections 6  (42.9%)
Severe respiratory  failure 4  (28.5%)
Cardiac  failure  2  (14.3%)
Other causes  2  (14.3%)
180 day  mortality  1  (5.55%)
1 year  mortality  2  (11.1%)
2 year  mortality  2  (11.1%)
4 year  mortality  4  (22.2%)
Overall  mortality  4  (22.2%)
Table  4  Variables  associated  with  mortality  in  MPV.
Variable Survivors  14 Deaths  4  p-value
Age  69  ±  8  75  ±  6  0.39
Sex (male)  7/14  3/4  0.06
FVC 1734  ±  399  1597  ±  492  0.11
FEV1 1399  ±  361  1320  ±  394  0.09
TLC 4460  ±  994  4230  ±  1070  0.06
paO2/FiO2 269  ±  23  254  ±  32  0.09
paCO2 53  ±  9  62  ±  6  0.05
pH 7.36  ±  0.02  7.35  ±  0.04  0.04
MIP 42  ±  7  34  ±  7  0.04
MEP 40  ±  3  38  ±  4  0.09
SNIP 49  ±  6  42  ±  3  0.05
P01 0.22  ±  0.09 0.24  ±  0.07  0.09
VT 356  ±  64  348  ±  52  0.12
Respiratory
frequency
17 ±  2 21  ±  3  0.04
AHI 23  ±  10  26  ±  8  0.08
ODI 36  ±  10  47  ±  9  0.03
Epworth  scale  13  ±  1  15  ±  2  0.08
Comorbidities  2  4  0.06
Cardiac  comor-
bidities
1  6  0.01
paO2, arterial oxygen pressure; paCO2, carbon dioxide arte-
rial pressure; MIP, maximal inspiratory pressure; MEP, maximal
expiratory pressure; SNIP, sniff nasal inspiratory pressure; P01,
inspiratory occlusion pressure for the ﬁrst 100 ms  of inspira-
tion; VT, tidal volume; AHI, apnea-hypopnea index; ODI, oxygen
desaturation index; tcPCO2, transcutaneous CO2 pressure; FVC,
Table  5  Comparison  of  the  MPV  group  and  the  control
group.
Variable  MPV  group  Control
group
p-value
Female  11  12  0.28
Male 7  6  0.33
Age 71.4  ±  10.9  69.1  ±  8.8  0.52
Height 163.9  ±  9.2  167.7  ±  4.1  0.19
Weight  74.0  ±  7.3  69.8  ±  4.9  0.19
Comorbidities  9  8  0.11
Cardiac
comorb
7 5  0.09
paO2 10.4  ±  4.9 8.5  ±  5.4 0.08
paCO2 −16.0  ±  6.6  −9.1  ±  4.3  0.09
pH 31.2  ±  19.6  17.9  ±  13.6  0.07
HCO3− −6.6  ±  2.2  −3.5  ±  1.8  0.06
FVC 115.8  ±  486.3  2.2  ±  651.1  0.01
FEV1 76.2  ±195.7  14.5  ±  211.5  0.03
TLC 188.9  ±  1051.0  26.7  ±  554.0  0.02
MIP 6.7  ±  13.2  3.7  ±  7.7  0.02
MEP 6.4  ±  12.6  5.1  ±  7.3  0.05
SNIP 9.2  ±  8.3  2.9  ±  6.1  0.03
P01 −0.1  ±  0.1  −0.1  ±  0.1  0.14
6MWT  19.5  ±  8.4  9.3  ±  7.2  0.04
BR −1.8  ±  1.8  −2.0  ±  1.5  0.07
EPSS −6.8  ±  2.1  −5.8  ±  2.2  0.12
AHI −15.9  ±  13.2  −17.5  ±  10.0  0.19
ODI −22.4  ±  10.5  −18.9  ±  7.5  0.24
MMRC  0.5  ±  0.0  0.5  ±  0.0  0.88
ICU readmis-
sions
28.5%  30.2%  0.07
180 day
mortality
5.55%  7.93%  0.03
360 day
mortality
11.1%  12.8%  0.03
720 day
mortality
22.2%  25.6%  0.05
1440 day
mortality
22.2%  23.4%  0.06
paO2, arterial oxygen pressure; paCO2, carbon dioxide arte-
rial pressure; MIP, maximal inspiratory pressure; MEP, maximal
expiratory pressure; SNIP, sniff nasal inspiratory pressure; P01,
inspiratory occlusion pressure for the ﬁrst 100 ms  of inspira-
tion; VT, tidal volume; AHI, apnea-hypopnea index; ODI, oxygen
desaturation index; FVC, forced vital capacity; FEV1, forced








in  180--360  and  720  day  mortality  compared  to  MPV  group.forced vital capacity; FEV1, forced expiratory volume 1 s; TLC,
total lung capacity.
Comparison  with  a  historical  group  treated  with
nocturnal NIV
The  comparison  of  the  group  treated  with  MPV  and  noctur-
nal  NIV  and  historical  group  treated  with  nocturnal  NIV  (plus
diurnal  NIV  only  if  needed)is  reported  in  Table  5.  The  con-
trol  patients  suffered  from  severe  kyphoscoliosis  previously
treated  with  NIV  without  adding  daytime  MPV.  Each  patient
used  NIV  at  least  12  h  per  day.  There  was  no  statistically
signiﬁcant  difference  in  the  time  NIV  was  used  between  the
two  groups  (15.3  ±  4.6  vs  12.2  ±  2.1  p  <  0.09).  These  patients
M
s
mbonate; MMRC scale, Modiﬁed Medical Research Council dyspnea
scale.
ere  treated  with  the  following  home  ventilators:  Resmed
dea  Ultra,  Resmed  VS  III,  Resmed  Elisee  150,Breas  Vivo  50
nd  Legendair  Covidien.  Eight  of  them  were  treated  with
PCV  and  double  limb  ventilator  circuit;  ten  of  these  used
ressure  support  ventilation  (PSV)  with  security  or  guaran-
eed  volume  and  single  limb  circuit  with  expiratory  valve.
atients  receiving  NIV  during  night  time  showed  an  increaseoreover  the  MPV  group  had  a  signiﬁcant  improvement  of
ome  respiratory  function  parameters  after  6  months  treat-

















































































and non-invasive mechanical ventilation in kyphoscoliosis: are0  
iscussion and  conclusions
ur  ﬁndings  demonstrated  improvement  in  clinical  symp-
oms,  blood  gases  and  nocturnal  ventilation,  sleep  related
arameters  and  HRQL  scores  in  our  patient  cohort.  These
mprovements  were  accompanied  by  a  signiﬁcant  increase
n  lung  volumes  and  respiratory  muscle  function  following
iurnal  ventilation  via  angled  mouthpiece  with  nocturnal
entilation  via  mask.  Ours  is  the  ﬁrst  study  describing  man-
gement  of  kyphoscoliotic  patients  following  an  episode  of
RF  using  diurnal  MPV  associated  with  nocturnal  ventila-
ion  via  a  mask.  Most  previous  studies  investigated  stable
atients  who  were  given  nocturnal  ventilation4,5,8,9,11,23--27
nd  demonstrated  the  effectiveness  of  nocturnal  ventila-
ion  in  relieving  symptoms,  improving  ABG  accompanied  by
 signiﬁcant  increase  in  lung  volumes  and  inspiratory  mus-
le  function.5,8,24--28 A  previous  study  reported  that  patients
ith  ARF  receiving  24  h/day  non-invasive  ventilation  for  a
ew  weeks  signiﬁcantly  improved  and  returned  to  baseline
ondition  after  about  four  weeks.3 Only  one  study  assessed
cute  kyphoscoliotic  patients  and  their  follow-up,  consid-
ring  not  only  improvements  in  clinical  symptoms,  ABG  or
ung  function,  but  also  treatment  compliance,  hospital  and
CU  readmission  and  treatment  compliance.1 Twenty-nine
atients  were  followed  for  at  least  12  months:  eight  patients
ere  readmitted  19  times.
Five  of  them  died  (a  4  years  mortality  rate  of  20.7%).  Only
H  and  6MWT  distance  signiﬁcantly  improved  after  NIV.1 No
mprovement  was  shown  in  paCO2,  paO2/FiO2 or  lung  vol-
mes.  NIV  in  pressure-support  mode  was  used  with  an  IPAP
et  to  obtain  VT  of  8--10  ml/kg.  The  authors  concluded  that
IV  improves  pulmonary  performance  in  the  long  term.1 The
ortality  rates  of  kyphoscoliosis  patients  with  long-term
omiciliary  NIV  therapy  has  been  reported  to  be  9.5%  at  two
ears,  20.7%  at  four  years  up  and  28.1%  at  ﬁve  years.1,29,31
redictors  of  mortality  were  rarely  investigated,  nor  were
o-morbidities.  Marti  et  al.31 suggested  that  a  high  level
aCO2 (>50  mmHg)  at  1  month  after  starting  NIV  and  the
resence  of  co-morbid  conditions  are  risk  factors  for  mor-
ality  in  patients  with  kyphoscoliosis  and  cardiopulmonary
o-morbidity  may  contribute  to  higher  paCO2 and  lower  paO2
evel,  worsening  the  prognosis  of  these  patients.10
Our  data  are  consistent  with  these  previous  studies.
atients  who  had  higher  cardiac  co-morbidities,  lower  pH,
IP  and  SNIP  and  higher  respiratory  frequency,  paCO2 and
DI  at  admission  tended  to  have  higher  mortality.  In  her
tudy  Kirani32 evaluated  209  patients  (30  in  MPV)  using
 questionnaire.  Her  patients  reported  that  MPV  use  was
orrelated  with  a  reduction  of  dyspnea  and  fatigue  along
ith  greater  facility  in  speaking  and  eating.  One  subject
hought  that  his  tracheotomy  could  have  been  avoided
f  he  had  started  using  MPV  earlier.  In  a  case  report
ard33 described  a  patient  with  severe  diurnal  acidosis  who
efused  oro-nasal  mask.  Standard  NIV  was  not  effective.
he  use  of  diurnal  MPV  provided  better  control  of  respira-
ory  failure,  allowed  independent  living  as  well  as  avoiding
racheotomy.
Our  study  has  some  limitations:  the  number  of  patients
ollowed  by  a  single  center;  sleep  data  were  limited;  clin-
cal  and  functional  data  were  only  recorded  at  six  month
ollow-up  visit  and  thus  cannot  be  correlated  with  mortality
r  hospital  re-admission.
1A.  Nicolini  et  al.
In  conclusion,  NIV  using  a  combination  of  mouthpiece  and
ask  in  severely  kyphoscoliotic  patients  improves  both  clin-
cal  and  functional  parameters.  As  clinicians  we  can  offer
ore  options  by  adding  daytime  MPV:  it  is  a  practical  and
afe  way  to  treat  ventilatory  insufﬁciency;  this  modality  pro-
otes  independent  living  and  provides  these  patients  an
nhanced  quality  of  life.
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